{"id":742241,"date":"2012-03-06T08:00:00","date_gmt":"2012-03-06T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/"},"modified":"2023-03-22T00:04:25","modified_gmt":"2023-03-22T04:04:25","slug":"merck-confirms-2012-full-year-guidance","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/","title":{"rendered":"Merck Confirms 2012 Full-Year Guidance"},"content":{"rendered":"<p class=\"bwalignc\">       Provides Guidance on First Quarter     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today re-confirmed its expectations for full-year 2012 non-GAAP EPS to<br \/>\n      be between $3.75 and $3.85, and the 2012 GAAP EPS range to be $2.04 to<br \/>\n      $2.30. The 2012 non-GAAP range excludes acquisition-related costs and<br \/>\n      costs related to restructuring programs.\n    <\/p>\n<p>\n      As previously noted, Merck expects full-year 2012 revenues to be at or<br \/>\n      near 2011 levels on a constant currency basis. At current exchange<br \/>\n      rates, sales would be unfavorably affected by about 2 to 3 percent.\n    <\/p>\n<p>\n      The company is providing guidance about its expectations for the first<br \/>\n      quarter of 2012 to help investors understand the impact of exchange in<br \/>\n      the quarter. With a first quarter Euro exchange rate of approximately<br \/>\n      $1.31\/Euro, currency is expected to have approximately a 1 to 2 percent<br \/>\n      unfavorable impact on sales in the first quarter. Merck expects<br \/>\n      first-quarter non-GAAP EPS to be between $0.95 and $0.98, and the GAAP<br \/>\n      EPS range to be $0.52 to $0.60.\n    <\/p>\n<p>\n      In addition, the company expects full-year 2012 non-GAAP R&amp;D expense to<br \/>\n      be at approximately the same level as in 2011 and expects its full-year<br \/>\n      2012 non-GAAP tax rate to be in the range of 23 to 25 percent.\n    <\/p>\n<p>\n      A reconciliation of anticipated full-year and first-quarter 2012 EPS as<br \/>\n      reported in accordance with GAAP to non-GAAP EPS that excludes certain<br \/>\n      items is provided in the table below.(1)\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          $ in millions, except EPS amounts\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>Full Year 2012<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          GAAP EPS\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $2.04 to $2.30\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Difference(2)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          1.71 to 1.55\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Non-GAAP EPS that excludes items listed below\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $3.75 to $3.85\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Acquisition-related costs(3)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $5,200 to $4,900\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Restructuring costs\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          1,100 to 800\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Net decrease (increase) in income before taxes\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          6,300 to 5,700\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Estimated income tax (benefit) expense\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          (1,110) to (985)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Decrease (increase) in net income\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $5,190 to $4,715\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          $ in millions, except EPS amounts\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>First Quarter 2012<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          GAAP EPS\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $0.52 to $0.60\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Difference2\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          0.43 to 0.38\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Non-GAAP EPS that excludes items listed below\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $0.95 to $0.98\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Acquisition-related costs3\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $1,300 to $1,200\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Restructuring costs\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          300 to 200\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Net decrease (increase) in income before taxes\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          1,600 to 1,400\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Estimated income tax (benefit) expense\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          (285) to (240)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Decrease (increase) in net income\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $1,315 to $1,160\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50274862&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=4ec33fbc084f7a491c5c346a33d2092d\"><span class=\"bwuline\">vip2-msd.com\/merckcom-migrated<\/span><\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that the expected synergies from the merger of Merck and<br \/>\n      Schering-Plough will not be realized, or will not be realized within the<br \/>\n      expected time period; the impact of pharmaceutical industry regulation<br \/>\n      and health care legislation; the risk that the businesses will not be<br \/>\n      integrated successfully; disruption from the merger making it more<br \/>\n      difficult to maintain business and operational relationships; Merck\u2019s<br \/>\n      ability to accurately predict future market conditions; dependence on<br \/>\n      the effectiveness of Merck\u2019s patents and other protections for<br \/>\n      innovative products; the risk of new and changing regulation and health<br \/>\n      policies in the U.S. and internationally and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50274862&amp;lan=en-US&amp;anchor=www.sec.gov%29.&amp;index=2&amp;md5=2c700c6b8204e9c6702dd91ddba7b2f2\"><span class=\"bwuline\">www.sec.gov<\/span>).<\/a>\n    <\/p>\n<p>\n      (1) Both non-GAAP and GAAP EPS guidance for 2012 assume the potential<br \/>\n      exercise by AstraZeneca of its Shares Option in mid-2012 and include the<br \/>\n      estimated associated impact on revenue and equity income from<br \/>\n      affiliates. They do not reflect any gain on the potential transaction,<br \/>\n      which would be reflected only in the company&#8217;s GAAP results.\n    <\/p>\n<p>\n      (2) Represents the difference between calculated GAAP EPS and calculated<br \/>\n      non-GAAP EPS which may be different than the amount calculated by<br \/>\n      dividing the impact of the excluded items by the weighted average shares.\n    <\/p>\n<p>\n      (3) Includes expenses for the amortization of intangible assets and<br \/>\n      amortization of purchase accounting adjustments to inventories<br \/>\n      recognized as a result of mergers and acquisitions, as well as<br \/>\n      intangible asset impairment charges. Also includes integration and other<br \/>\n      costs associated with mergers and acquisitions.\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120511005620r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ron Rogers, 908-423-6449<br \/>or<br \/>Investors:<br \/>Alex        Kelly, 908-423-5185     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Provides Guidance on First Quarter Merck (NYSE: MRK), known as MSD outside the United States and Canada, today re-confirmed its expectations for full-year 2012 non-GAAP EPS to be between $3.75 and $3.85, and the 2012 GAAP EPS range to be $2.04 to $2.30. The 2012 non-GAAP range excludes acquisition-related costs and costs related to restructuring programs. As previously noted, Merck expects full-year 2012 revenues to be at or near 2011 levels on a constant currency basis. At current exchange rates, sales would be unfavorably affected by about 2 to 3 percent. The company is providing guidance about its expectations for the first quarter of 2012 to help investors understand the impact of exchange in the quarter. With a first quarter Euro exchange rate of approximately $1.31\/Euro, currency is expected to have approximately a 1 to 2 percent unfavorable impact on sales in the first quarter. Merck expects first-quarter non-GAAP EPS to be between $0.95 and $0.98, and the GAAP EPS range to be<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,52,289],"class_list":["post-742241","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-financial-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Confirms 2012 Full-Year Guidance - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Confirms 2012 Full-Year Guidance - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Provides Guidance on First Quarter Merck (NYSE: MRK), known as MSD outside the United States and Canada, today re-confirmed its expectations for full-year 2012 non-GAAP EPS to be between $3.75 and $3.85, and the 2012 GAAP EPS range to be $2.04 to $2.30. The 2012 non-GAAP range excludes acquisition-related costs and costs related to restructuring programs. As previously noted, Merck expects full-year 2012 revenues to be at or near 2011 levels on a constant currency basis. At current exchange rates, sales would be unfavorably affected by about 2 to 3 percent. The company is providing guidance about its expectations for the first quarter of 2012 to help investors understand the impact of exchange in the quarter. With a first quarter Euro exchange rate of approximately $1.31\/Euro, currency is expected to have approximately a 1 to 2 percent unfavorable impact on sales in the first quarter. Merck expects first-quarter non-GAAP EPS to be between $0.95 and $0.98, and the GAAP EPS range to be\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:25+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120511005620r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-confirms-2012-full-year-guidance\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-confirms-2012-full-year-guidance\\\/\",\"name\":\"Merck Confirms 2012 Full-Year Guidance - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-confirms-2012-full-year-guidance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-confirms-2012-full-year-guidance\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120511005620r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2012-03-06T08:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-confirms-2012-full-year-guidance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-confirms-2012-full-year-guidance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-confirms-2012-full-year-guidance\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120511005620r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120511005620r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-confirms-2012-full-year-guidance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Confirms 2012 Full-Year Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Confirms 2012 Full-Year Guidance - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/","og_locale":"en_US","og_type":"article","og_title":"Merck Confirms 2012 Full-Year Guidance - Merck.com","og_description":"Provides Guidance on First Quarter Merck (NYSE: MRK), known as MSD outside the United States and Canada, today re-confirmed its expectations for full-year 2012 non-GAAP EPS to be between $3.75 and $3.85, and the 2012 GAAP EPS range to be $2.04 to $2.30. The 2012 non-GAAP range excludes acquisition-related costs and costs related to restructuring programs. As previously noted, Merck expects full-year 2012 revenues to be at or near 2011 levels on a constant currency basis. At current exchange rates, sales would be unfavorably affected by about 2 to 3 percent. The company is providing guidance about its expectations for the first quarter of 2012 to help investors understand the impact of exchange in the quarter. With a first quarter Euro exchange rate of approximately $1.31\/Euro, currency is expected to have approximately a 1 to 2 percent unfavorable impact on sales in the first quarter. Merck expects first-quarter non-GAAP EPS to be between $0.95 and $0.98, and the GAAP EPS range to be","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:25+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120511005620r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/","name":"Merck Confirms 2012 Full-Year Guidance - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120511005620r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2012-03-06T08:00:00+00:00","dateModified":"2023-03-22T04:04:25+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120511005620r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120511005620r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-confirms-2012-full-year-guidance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Confirms 2012 Full-Year Guidance"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"788c49d9-9bad-48e5-99dc-3c2c851f1a97","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Confirms-2012-Full-Year-Guidance-2012.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742241\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742241"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}